The expressions ofCD8A,CXCL9,NKX2-1,SFTA3,IDO1, andIL2RB in the response group was markedly higher, suggesting that six M1 genes were indeed involved in NSCLC sensitivity to camrelizumab plus chemotherapy (Figure 6A‒F). Here, IDO1 is linked to non-small cell lung carcinoma.